<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631617</url>
  </required_header>
  <id_info>
    <org_study_id>120159</org_study_id>
    <secondary_id>12-AR-0159</secondary_id>
    <nct_id>NCT01631617</nct_id>
  </id_info>
  <brief_title>Effects of Treatments on Atopic Dermatitis</brief_title>
  <official_title>Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have&#xD;
      infections with S. aureus bacteria. Researchers want to study how eczema treatments affect&#xD;
      the number and the type of bacteria on the skin.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To study the effect of eczema treatments on skin bacteria.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis.&#xD;
&#xD;
        -  Healthy volunteers between 18 and 40 years of age with no history of eczema.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history. Research samples&#xD;
           will be collected. Skin biopsies may also be performed.&#xD;
&#xD;
        -  All participants will be assigned to one of several study groups.&#xD;
&#xD;
        -  This study will last for up to 1 year. Healthy volunteers must not have taken&#xD;
           antibiotics in the year before the start of the study.&#xD;
&#xD;
        -  All participants will have regular study visits during their 1-year participation. More&#xD;
           research samples will be collected at these visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
        -  The use of antibiotics has revolutionized medicine, yet the impact of antimicrobials on&#xD;
           the human microbiome is incompletely understood.&#xD;
&#xD;
        -  Antimicrobial treatments, including topical and systemic antibiotics, are highly&#xD;
           effective and are frequently used to manage disease flares of AD. Concomitant use of&#xD;
           dilute bleach baths reduces the clinical severity of AD in patients with clinical signs&#xD;
           of bacterial skin infections.&#xD;
&#xD;
        -  The longitudinal impact of various antimicrobials on the human microbiome, particularly&#xD;
           in skin, has not been systematically investigated.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      -To characterize microbiome alterations in healthy adult volunteers (Cohorts 1 and 2) and&#xD;
      patients with AD (Cohort 3) after antimicrobial treatments.&#xD;
&#xD;
      ELIGIBILITY:&#xD;
&#xD;
        -  All subjects must be co-enrolled in NIH protocol 08-HG-0059&#xD;
&#xD;
        -  (Cohorts 1 and 2) Healthy volunteers aged 18 to 50 years with no history of AD&#xD;
&#xD;
        -  (Cohort 1 and 2) No prior use of systemic antibiotics in preceding 12 months&#xD;
&#xD;
        -  (Cohort 3) Subjects 2-50 years with atopic dermatitis with symptoms of active bacterial&#xD;
           infection&#xD;
&#xD;
        -  (Cohort 3) Objective SCORAD (SCORing Atopic Dermatitis) score of greater than or equal&#xD;
           to 15 indicating moderate-to-severe disease&#xD;
&#xD;
      DESIGN:&#xD;
&#xD;
        -  A prospective, interventional, longitudinal study examining changes in microbiome&#xD;
           resulting from randomized, placebo-controlled, investigator-blinded antimicrobial&#xD;
           treatments.&#xD;
&#xD;
        -  Subjects in Cohort 1 will be randomized to take one of 4 open label antibiotic regimens.&#xD;
&#xD;
        -  Subjects from Cohort 2 will be will be randomized to one of four possible blinded&#xD;
           treatment combinations of study baths and antibiotics.&#xD;
&#xD;
        -  Subjects in Cohort 3 will be randomized to a cephalexin regimen with or without study&#xD;
           baths.&#xD;
&#xD;
        -  All subjects will undergo longitudinal microbiome sampling.&#xD;
&#xD;
        -  AD patients will undergo clinical assessment to determine responses of skin infections&#xD;
           to treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2012</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize microbiome alterations</measure>
    <time_frame>2 weeks</time_frame>
    <description>Difference in Shannon Diversity Indices (SDI) from baseline to day 14.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Eczema</condition>
  <condition>Dermatitis</condition>
  <condition>Skin Diseases, Genetic</condition>
  <condition>Dermatitis, Atopic</condition>
  <condition>Skin Diseases</condition>
  <arm_group>
    <arm_group_label>1A/Cephalexin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cephalexin + Placebo bleach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B/TMP/SMX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TMP/SMZ DS 800 /160 orally every 12 hours for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1C/Doxycycline 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxycycline 100 mg orally every 12 hours for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1D/Doxycycline 20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxycycline 20 mg orally every 12 hours for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A/Cephalexin + Dilute bleach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B/Cephalexin + Placebo bleach</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Systemic antibiotics (Cephalexin) + placebo study bath liquid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2C/Placebo capsules + Dilute bleach</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules + dilute bleach study bath liquid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2D/Placebo capsules + Placebo bleach</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules + placebo study bath liquid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3A/Cephalexin + Dilute bleach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3B/Cephalexin + Placebo bleach</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Systemic antibiotics (Cephalexin) + placebo study bath liquid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim/sulfamethoxazole (TMP/SMZ)</intervention_name>
    <description>800/160 orally every 12 hours for 14 days</description>
    <arm_group_label>1B/TMP/SMX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>500 mg orally every 8 hours for 14 days</description>
    <arm_group_label>1A/Cephalexin</arm_group_label>
    <arm_group_label>1C/Doxycycline 100</arm_group_label>
    <arm_group_label>2A/Cephalexin + Dilute bleach</arm_group_label>
    <arm_group_label>2B/Cephalexin + Placebo bleach</arm_group_label>
    <arm_group_label>3A/Cephalexin + Dilute bleach</arm_group_label>
    <arm_group_label>3B/Cephalexin + Placebo bleach</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days</description>
    <arm_group_label>1D/Doxycycline 20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium hypochlorite</intervention_name>
    <description>6 % dilute bleach</description>
    <arm_group_label>1C/Doxycycline 100</arm_group_label>
    <arm_group_label>2A/Cephalexin + Dilute bleach</arm_group_label>
    <arm_group_label>2C/Placebo capsules + Dilute bleach</arm_group_label>
    <arm_group_label>3A/Cephalexin + Dilute bleach</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Capsule orally every 8 hours daily for 14 days</description>
    <arm_group_label>2C/Placebo capsules + Dilute bleach</arm_group_label>
    <arm_group_label>2D/Placebo capsules + Placebo bleach</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Sodium hypochlorite</intervention_name>
    <description>Three times a week for 14 days</description>
    <arm_group_label>2B/Cephalexin + Placebo bleach</arm_group_label>
    <arm_group_label>2D/Placebo capsules + Placebo bleach</arm_group_label>
    <arm_group_label>3B/Cephalexin + Placebo bleach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Cohorts 1 and 2: Healthy Volunteers&#xD;
&#xD;
        Males and females aged 18-50 years.&#xD;
&#xD;
          -  Subjects must participate fully and be willing to comply with the procedures of the&#xD;
             protocol&#xD;
&#xD;
          -  Subjects must be co-enrolled in NIH protocol 08-HG-0059&#xD;
&#xD;
          -  Ability of subject to understand and provide written informed consent.&#xD;
&#xD;
          -  Access to bathing facilities&#xD;
&#xD;
          -  Ability to swallow capsules or tablets&#xD;
&#xD;
        Cohort 3: Atopic Dermatitis Patients&#xD;
&#xD;
          -  Subjects must be aged 2-50 years.&#xD;
&#xD;
          -  Subjects must be co-enrolled in NIH protocol 08-HG-0059&#xD;
&#xD;
          -  Subjects must have a diagnosis of atopic dermatitis on the basis of the criteria&#xD;
             defined by UK Working Party s Diagnostic Criteria for Atopic Dermatitis&#xD;
&#xD;
          -  Subjects must have a primary care provider&#xD;
&#xD;
          -  Subjects must have an Objective SCORAD (SCORing Atopic Dermatitis) of greater than or&#xD;
             equal to 15 indicating AD severity of moderate to severe&#xD;
&#xD;
          -  Prior to initiation of randomized treatment, subjects must have signs of bacterial&#xD;
             skin infections (skin weeping, crusting, and/or pustules)&#xD;
&#xD;
          -  Access to bathing facilities&#xD;
&#xD;
          -  All subjects and/or their Legally Authorized Representative (LAR) must have the&#xD;
             ability and agree to participate fully and comply with&#xD;
&#xD;
        the procedures of the protocol and provide informed consent. Pediatric patients will be&#xD;
        included in age appropriate discussions and&#xD;
&#xD;
        age appropriate assent will be obtained in accordance with NIH guidelines.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Cohorts 1 and 2: Healthy Volunteers&#xD;
&#xD;
          -  Does not meet inclusion criteria&#xD;
&#xD;
          -  Any female with symptoms and/or serum hormone levels consistent with perimenopause&#xD;
&#xD;
          -  Use of systemic antibiotics in 12 months preceding baseline sampling&#xD;
&#xD;
          -  Use of swimming pools, hot tubs, or whirlpools in 7 days preceding baseline sampling&#xD;
&#xD;
          -  Use of topical or oral complementary/alternative medicine (CAM) agents within 4 weeks&#xD;
             of initiation of treatment&#xD;
&#xD;
          -  Known allergic reaction to sulfa, beta-lactam, or tetracycline class drugs; or&#xD;
             lidocaine or epinephrine&#xD;
&#xD;
          -  Family history of toxic epidermal necrolysis&#xD;
&#xD;
          -  Known allergy or sensitivity to sodium hypochlorite (NaOCl)&#xD;
&#xD;
          -  History of AD and asthma&#xD;
&#xD;
          -  Inability to comply with the requirements of the protocol&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Subjects with a primary or acquired immunodeficiency, including HIV seropositiviy&#xD;
&#xD;
          -  Any chronic past or present medical illness, including chronic skin diseases like&#xD;
             psoriasis&#xD;
&#xD;
          -  Subjects receiving or planning to receive an IND agent, ultraviolet light therapy,&#xD;
             monoclonal antibodies, or systemic immunosuppressants&#xD;
&#xD;
          -  Subjects who provide direct healthcare or reside in healthcare facilities or in&#xD;
             non-hospital settings such as clinics, assisted living facilities, homeless shelters,&#xD;
             jails and prisons as well as subjects with frequent exposure to laboratory animals&#xD;
&#xD;
        Cohort 3: Atopic Dermatitis Patients&#xD;
&#xD;
          -  Does not meet inclusion criteria&#xD;
&#xD;
          -  Any female with symptoms and/or serum hormone levels consistent with perimenopause&#xD;
&#xD;
          -  Known allergic reaction to beta-lactam class drugs, lidocaine, or epinephrine&#xD;
&#xD;
          -  Family history of toxic epidermal necrolysis&#xD;
&#xD;
          -  Known allergic reaction to sodium hypochlorite (NaOCl)&#xD;
&#xD;
          -  Use of systemic antibiotics within 8 weeks, or topical antibiotics on intended&#xD;
             sampling sites within 3 weeks, prior to baseline sampling&#xD;
&#xD;
          -  Use of topical corticosteroids on all intended sampling sites within 7 days, prior to&#xD;
             baseline sampling&#xD;
&#xD;
          -  Use of topical or oral CAM agents within 4 weeks of initiation of treatment&#xD;
&#xD;
          -  Subjects with known primary or acquired immunodeficiency&#xD;
&#xD;
          -  Subjects with unstable or uncontrolled medical conditions that could require&#xD;
             hospitalization during the initial month of the study or who have been hospitalized&#xD;
             for treatment of these conditions in the one month prior to baseline sampling&#xD;
&#xD;
          -  Subjects receiving or planning to receive an IND agent, ultraviolet light therapy,&#xD;
             monoclonal antibodies, or systemic immunosuppressants within 7 days or 5 half-lives&#xD;
             (whichever is the longer time period) of initiating treatment on this protocol&#xD;
&#xD;
          -  Subjects who are currently receiving or have received chemotherapy or radiation for&#xD;
             treatment of malignancies within the previous 6 months&#xD;
&#xD;
          -  Pregnancy or lactating&#xD;
&#xD;
          -  Pregnant or lactating females in all cohorts are excluded from participating due to&#xD;
             the potential effects of the above listed antimicrobials on the developing human fetus&#xD;
             or nursing infant; listed in Sections 11.1 through 11.5. Females of childbearing&#xD;
             potential must agree to use adequate contraception (hormonal or barrier method of&#xD;
             birth control; abstinence) prior to study entry and for the duration of study&#xD;
             participation. Should a woman become pregnant or suspect she is pregnant while she is&#xD;
             participating in this study, she should inform her treating physician immediately.&#xD;
             Lactating mothers will discontinue breastfeeding prior to study enrollment.&#xD;
&#xD;
          -  Smokers and subjects who use smokeless tobacco products are excluded in all cohorts&#xD;
             due to tobacco s unknown impact on human oral mucosa and microflora.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidi H Kong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Glenna Banania</last_name>
    <phone>(301) 402-6225</phone>
    <email>glenna.banania@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidi H Kong, M.D.</last_name>
    <phone>(301) 827-2460</phone>
    <email>konghe@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2012-AR-0159.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>September 10, 2021</verification_date>
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <last_update_submitted>September 11, 2021</last_update_submitted>
  <last_update_submitted_qc>September 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Investigator-Blinded</keyword>
  <keyword>Skin Biopsy</keyword>
  <keyword>Randomized</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Skin Diseases, Genetic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Sodium Hypochlorite</mesh_term>
    <mesh_term>Eusol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

